MoonLake Immunotherapeutics (MLTX) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does MoonLake Immunotherapeutics Do?
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland. MoonLake Immunotherapeutics (MLTX) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Jorge Santos da Silva and employs approximately 2 people. With a market capitalization of $1.2B, MLTX is one of the notable companies in the Healthcare sector.
MoonLake Immunotherapeutics (MLTX) Stock Rating — Reduce (April 2026)
As of April 2026, MoonLake Immunotherapeutics receives a Reduce rating with a composite score of 27.7/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.MLTX ranks #2,785 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, MoonLake Immunotherapeutics ranks #384 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
MLTX Stock Price and 52-Week Range
MoonLake Immunotherapeutics (MLTX) currently trades at $18.37. The stock lost $1.04 (5.4%) in the most recent trading session. The 52-week high for MLTX is $62.75, which means the stock is currently trading -70.7% from its annual peak. The 52-week low is $5.95, putting the stock 208.7% above its annual trough. Recent trading volume was 692K shares, suggesting relatively thin trading activity.
Is MLTX Overvalued or Undervalued? — Valuation Analysis
MoonLake Immunotherapeutics (MLTX) carries a value factor score of 19/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 4.02x, versus the sector average of 2.75x.
At current multiples, MoonLake Immunotherapeutics trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.
MoonLake Immunotherapeutics Profitability — ROE, Margins, and Quality Score
MoonLake Immunotherapeutics (MLTX) earns a quality factor score of 24/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -66.8%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -47.9% versus the sector average of -33.1%.
Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.
MLTX Debt, Balance Sheet, and Financial Health
MoonLake Immunotherapeutics has a debt-to-equity ratio of 24.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 9.27x, indicating strong short-term liquidity. Total debt on the balance sheet is $74M. Cash and equivalents stand at $351M.
MLTX has a beta of 0.78, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for MoonLake Immunotherapeutics is 28/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.
MoonLake Immunotherapeutics Revenue and Earnings History — Quarterly Trend
In TTM 2026, MoonLake Immunotherapeutics reported revenue of $0 and earnings per share (EPS) of $-3.53. Net income for the quarter was $-203M. Operating income came in at $-223M.
In FY 2025, MoonLake Immunotherapeutics reported revenue of $0 and earnings per share (EPS) of $-3.53. Net income for the quarter was $-230M. Operating income came in at $-245M.
In Q3 2025, MoonLake Immunotherapeutics reported revenue of $0 and earnings per share (EPS) of $-1.10. Net income for the quarter was $-71M. Operating income came in at $-71M.
In Q2 2025, MoonLake Immunotherapeutics reported revenue of $0 and earnings per share (EPS) of $-0.87. Net income for the quarter was $-56M. Operating income came in at $-61M.
Over the past 8 quarters, MoonLake Immunotherapeutics has experienced revenue contraction from $0 to $0. Investors analyzing MLTX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
MLTX Dividend Yield and Income Analysis
MoonLake Immunotherapeutics (MLTX) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.
MLTX Momentum and Technical Analysis Profile
MoonLake Immunotherapeutics (MLTX) has a momentum factor score of 23/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 64/100 reflects moderate short selling activity.
MLTX vs Competitors — Healthcare Sector Ranking and Peer Comparison
Within the Healthcare sector, MoonLake Immunotherapeutics (MLTX) ranks #384 out of 838 stocks based on the Blank Capital composite score. This places MLTX in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.
Comparing MLTX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full MLTX vs S&P 500 (SPY) comparison to assess how MoonLake Immunotherapeutics stacks up against the broader market across all factor dimensions.
MLTX Next Earnings Date
No upcoming earnings date has been announced for MoonLake Immunotherapeutics (MLTX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy MLTX? — Investment Thesis Summary
The quantitative profile for MoonLake Immunotherapeutics suggests caution. The quality score of 24/100 flags below-average profitability. The value score of 19/100 indicates premium valuation. Momentum is weak at 23/100, a headwind for near-term performance. High volatility (stability score 28/100) increases portfolio risk.
In summary, MoonLake Immunotherapeutics (MLTX) earns a Reduce rating with a composite score of 27.7/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on MLTX stock.
Related Resources for MLTX Investors
Explore more research and tools: MLTX vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare MLTX head-to-head with peers: MLTX vs AZN, MLTX vs SLGL, MLTX vs VMD.